Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Α-Ethyltryptamine
α-Ethyltryptamine (αET, AET), also known as etryptamine, is an entactogen and stimulant drug of the tryptamine family. It was originally developed and marketed as an antidepressant under the brand name Monase by Upjohn in the 1960s before being withdrawn due to toxicity.
Side effects of αET include facial flushing, headache, gastrointestinal distress, insomnia, irritability, appetite loss, and sedation, among others. A rare side effect of αET is agranulocytosis. αET acts as a releasing agent of serotonin, norepinephrine, and dopamine, as a weak serotonin receptor agonist, and as a weak monoamine oxidase inhibitor. It may also produce serotonergic neurotoxicity. αET is a substituted tryptamine and is closely related to α-methyltryptamine (αMT) and other α-alkylated tryptamines.
αET was first described in 1947. It was used as an antidepressant for about a year around 1961. The drug started being used recreationally in the 1980s and several deaths have been reported. αET is a controlled substance in various countries, including the United States and United Kingdom. There has been renewed interest in αET, for instance as an alternative to MDMA, with the development of psychedelics and entactogens as medicines in the 2020s.
αET was previously used medically as an antidepressant and "psychic energizer" to treat people with depression. It was used for this indication under the brand name Monase. The drug was available pharmaceutically as the acetate salt under the brand name Monase as 15 mg oral tablets.
αET is reported to have entactogen and weak psychostimulant effects. Euphoria, increased energy, openness, and empathy have been specifically reported. Unlike αMT and other tryptamines, αET is not reported to have psychedelic or hallucinogenic effects. The drug is described as less stimulating and intense than MDMA ("ecstasy") but as otherwise having entactogenic effects resembling those of MDMA. The dose of αET used recreationally has been reported to be 100 to 160 mg, its onset of action has been reported to be 0.5 to 1.5 hours, and its duration of action at the preceding doses is described as 6 to 8 hours. Rapid tolerance to repeated administration of αET has been described.
Side effects of αET at antidepressant doses have included facial flushing, headache, gastrointestinal distress, insomnia, irritability, and sedation. Additional side effects of αET at recreational doses have included appetite loss and feelings of intoxication. Feelings of lethargy and sedation can occur once the drug wears off.
As with many other serotonin releasing agents, toxicity, such as serotonin syndrome, can occur when excessive doses are taken or when combined with certain drugs such as monoamine oxidase inhibitors (MAOIs). Several deaths have been associated with recreational use of αET.
Rarely, agranulocytosis has occurred with prolonged administration of αET at antidepressant doses and has been said to have resulted in several cases and/or deaths.
Hub AI
Α-Ethyltryptamine AI simulator
(@Α-Ethyltryptamine_simulator)
Α-Ethyltryptamine
α-Ethyltryptamine (αET, AET), also known as etryptamine, is an entactogen and stimulant drug of the tryptamine family. It was originally developed and marketed as an antidepressant under the brand name Monase by Upjohn in the 1960s before being withdrawn due to toxicity.
Side effects of αET include facial flushing, headache, gastrointestinal distress, insomnia, irritability, appetite loss, and sedation, among others. A rare side effect of αET is agranulocytosis. αET acts as a releasing agent of serotonin, norepinephrine, and dopamine, as a weak serotonin receptor agonist, and as a weak monoamine oxidase inhibitor. It may also produce serotonergic neurotoxicity. αET is a substituted tryptamine and is closely related to α-methyltryptamine (αMT) and other α-alkylated tryptamines.
αET was first described in 1947. It was used as an antidepressant for about a year around 1961. The drug started being used recreationally in the 1980s and several deaths have been reported. αET is a controlled substance in various countries, including the United States and United Kingdom. There has been renewed interest in αET, for instance as an alternative to MDMA, with the development of psychedelics and entactogens as medicines in the 2020s.
αET was previously used medically as an antidepressant and "psychic energizer" to treat people with depression. It was used for this indication under the brand name Monase. The drug was available pharmaceutically as the acetate salt under the brand name Monase as 15 mg oral tablets.
αET is reported to have entactogen and weak psychostimulant effects. Euphoria, increased energy, openness, and empathy have been specifically reported. Unlike αMT and other tryptamines, αET is not reported to have psychedelic or hallucinogenic effects. The drug is described as less stimulating and intense than MDMA ("ecstasy") but as otherwise having entactogenic effects resembling those of MDMA. The dose of αET used recreationally has been reported to be 100 to 160 mg, its onset of action has been reported to be 0.5 to 1.5 hours, and its duration of action at the preceding doses is described as 6 to 8 hours. Rapid tolerance to repeated administration of αET has been described.
Side effects of αET at antidepressant doses have included facial flushing, headache, gastrointestinal distress, insomnia, irritability, and sedation. Additional side effects of αET at recreational doses have included appetite loss and feelings of intoxication. Feelings of lethargy and sedation can occur once the drug wears off.
As with many other serotonin releasing agents, toxicity, such as serotonin syndrome, can occur when excessive doses are taken or when combined with certain drugs such as monoamine oxidase inhibitors (MAOIs). Several deaths have been associated with recreational use of αET.
Rarely, agranulocytosis has occurred with prolonged administration of αET at antidepressant doses and has been said to have resulted in several cases and/or deaths.